{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:21:17Z","timestamp":1786980077654,"version":"build-2736575974"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00393-015-0018-6","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T08:54:34Z","timestamp":1452761674000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR-Therapie muskuloskelettaler Schmerzen","DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain"],"prefix":"10.1007","volume":"75","author":[{"name":"Kommission Pharmakotherapie der DGRh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Bolten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reiter-Niesert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. O.","family":"Stichtenoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2007.06.004","volume":"11","author":"GP Aithal","year":"2007","unstructured":"Aithal GP, Day CP (2007) Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 11:563\u2013575 (vi\u2013vii)","journal-title":"Clin Liver Dis"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2174\/1381612053764904","volume":"11","author":"US Akarca","year":"2005","unstructured":"Akarca US (2005) Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. Curr Pharm Des 11:1779\u20131793","journal-title":"Curr Pharm Des"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/rheumatology\/keu480","volume":"54","author":"N Alcorn","year":"2015","unstructured":"Alcorn N, Madhok R (2015) Non-steroidal anti-inflammatory drugs and venous thromboembolism. Rheumatology (Oxford) 54:570\u2013571","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"18_CR4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1532-5415.2009.02376.x","volume":"57","author":"American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons","year":"2009","unstructured":"American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009) Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331\u20131346","journal-title":"J Am Geriatr Soc"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.28.5.527","volume":"28","author":"CP Armstrong","year":"1987","unstructured":"Armstrong CP, Blower AL (1987) Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527\u2013532","journal-title":"Gut"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","volume":"165","author":"TJ Aw","year":"2005","unstructured":"Aw TJ, Haas SJ, Liew D et al (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490\u2013496","journal-title":"Arch Intern Med"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2710.2011.01313.x","volume":"37","author":"K Awa","year":"2012","unstructured":"Awa K, Satoh H, Hori S et al (2012) Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic\/pharmacodynamic model. J Clin Pharm Ther 37:469\u2013474","journal-title":"J Clin Pharm Ther"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1590-8658(00)80821-X","volume":"32","author":"G Bianchi Porro","year":"2000","unstructured":"Bianchi Porro G, Lazzaroni M, Imbesi V et al (2000) Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 32:201\u2013208","journal-title":"Dig Liver Dis"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2036.1998.00312.x","volume":"12","author":"G Bianchi Porro","year":"1998","unstructured":"Bianchi Porro G, Lazzaroni M, Manzionna G et al (1998) Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 12:355\u2013360","journal-title":"Aliment Pharmacol Ther"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.38273.626655.63","volume":"329","author":"JM Bjordal","year":"2004","unstructured":"Bjordal JM, Ljunggren AE, Klovning A et al (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329:1317","journal-title":"BMJ"},{"key":"18_CR11","first-page":"317","volume":"48","author":"W Bolten","year":"1989","unstructured":"Bolten W, Salzmann G, Goldmann R et al (1989) Plasma and tissue concentrations of biphenylacetic acid following 1 week oral fenbufen medication and topical administration of Felbinac gel on the knee joint. Z Rheumatol 48:317\u2013322","journal-title":"Z Rheumatol"},{"key":"18_CR12","first-page":"374","volume":"49","author":"W Bolten","year":"1990","unstructured":"Bolten W, Waldorf-Bolten E, Sarfert D et al (1990) Pharmacokinetic studies following 2 and 4-week Felbinac gel administration to the knee joint. Z Rheumatol 49:374\u2013377","journal-title":"Z Rheumatol"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00393-012-1026-4","volume":"71","author":"WW Bolten","year":"2012","unstructured":"Bolten WW, Reiter S, Kommission Pharmakotherapie der Deutschen Gesellschaft f\u00fcr Rheumatologie (2012) Empfehlungen zur symptomatischen Therapie mit Opioidanalgetika bei rheumatischen Schmerzen. Z Rheumatol 71:816\u2013822","journal-title":"Z Rheumatol"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"3D","DOI":"10.1016\/S0002-9149(02)02231-2","volume":"89","author":"C Bombardier","year":"2002","unstructured":"Bombardier C (2002) An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 89:3D\u20139D","journal-title":"Am J Cardiol"},{"key":"18_CR15","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520\u20131528","journal-title":"N Engl J Med"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.lpm.2012.09.016","volume":"42","author":"C Bourne","year":"1983","unstructured":"Bourne C, Charpiat B, Charhon N et al (1983) Emergent adverse effects of proton pump inhibitors. Presse Med 42:e53\u2013e62","journal-title":"Presse Med"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0002-9343(00)00629-X","volume":"110","author":"J Brun","year":"2001","unstructured":"Brun J, Jones R (2001) Nonsteroidal anti-inflammatory drug-associated dyspepsia: the scale of the problem. Am J Med 110:12\u201313","journal-title":"Am J Med"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.prostaglandins.2006.05.019","volume":"82","author":"ML Capone","year":"2007","unstructured":"Capone ML, Tacconelli S, Di Francesco L et al (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 82:85\u201394","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/jpet.107.122283","volume":"322","author":"ML Capone","year":"2007","unstructured":"Capone ML, Tacconelli S, Sciulli MG et al (2007) Human pharmacology of naproxen sodium. J Pharmacol Exp Ther 322:453\u2013460","journal-title":"J Pharmacol Exp Ther"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"F Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809\u20131817","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"18_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.1988.tb00761.x","volume":"2","author":"TC Chalmers","year":"1988","unstructured":"Chalmers TC, Berrier J, Hewitt P et al (1988) Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther 2(Suppl 1):9\u201326","journal-title":"Aliment Pharmacol Ther"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/HJH.0b013e3283310dc9","volume":"27","author":"CC Chan","year":"2009","unstructured":"Chan CC, Reid CM, Aw TJ et al (2009) Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 27:2332\u20132341","journal-title":"J Hypertens"},{"issue":"4","key":"18_CR23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1053\/j.gastro.2004.07.010","volume":"127","author":"FK Chan","year":"2004","unstructured":"Chan FK, Hung LC, Suen BY et al (2004) Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127(4):1038\u20131043","journal-title":"Gastroenterology"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","volume":"347","author":"FK Chan","year":"2002","unstructured":"Chan FK, Hung LC, Suen BY et al (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347:2104\u20132110","journal-title":"N Engl J Med"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","volume":"376","author":"FK Chan","year":"2010","unstructured":"Chan FK, Lanas A, Scheiman J et al (2010) Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376:173\u2013179","journal-title":"Lancet"},{"key":"18_CR26","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","volume":"369","author":"FK Chan","year":"2007","unstructured":"Chan FK, Wong VW, Suen BY et al (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369:1621\u20131626","journal-title":"Lancet"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pds.2140","volume":"20","author":"C-H Chang","year":"2011","unstructured":"Chang C-H, Chen H-C, Lin J-W et al (2011) Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf 20:763\u2013771","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"18_CR28","first-page":"1","volume":"12","author":"YF Chen","year":"2008","unstructured":"Chen YF, Jobanputra P, Barton P et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12:1\u2013278 (iii)","journal-title":"Health Technol Assess"},{"key":"18_CR29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJM198403013100905","volume":"310","author":"DM Clive","year":"1984","unstructured":"Clive DM, Stoff JS (1984) Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 310:563\u2013572","journal-title":"N Engl J Med"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/ket133","volume":"52","author":"PG Conaghan","year":"2013","unstructured":"Conaghan PG, Dickson J, Bolten W et al (2013) A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 52:1303\u20131312","journal-title":"Rheumatology (Oxford)"},{"key":"18_CR31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Coxib and Traditional NSAID Trialists\u2019 (CNT) Collaboration","year":"2013","unstructured":"Coxib and Traditional NSAID Trialists\u2019 (CNT) Collaboration (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779","journal-title":"Lancet"},{"key":"18_CR32","first-page":"CD007400","volume":"9","author":"S Derry","year":"2012","unstructured":"Derry S, Moore RA, Rabbie R (2012) Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 9:CD007400","journal-title":"Cochrane Database Syst Rev"},{"key":"18_CR33","unstructured":"Deutsche Fachinformationen (2015) FachInfo-Service \u2013 Fachinformationsverzeichnis Deutschland. Rote Liste\u00ae Service GmbH, Frankfurt\/Main. http:\/\/www.fachinfo.de\/"},{"key":"18_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados M, Simon P, Braun J et al (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70:249\u2013251","journal-title":"Ann Rheum Dis"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1001\/jama.2013.5794","volume":"309","author":"D Dowell","year":"2013","unstructured":"Dowell D, Kunins HV, Farley TA (2013) Opioid analgesics \u2013 risky drugs, not risky patients. JAMA 309:2219\u20132220","journal-title":"JAMA"},{"key":"18_CR36","unstructured":"Drug Information System: AiDKlinik\u00ae Release 1.9.16 Revision 23502 (2015) Dosing GmbH Heidelberg"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","volume":"142","author":"G Dueckers","year":"2012","unstructured":"Dueckers G, Guellac N, Arbogast M et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142:176\u2013193","journal-title":"Clin Immunol"},{"key":"18_CR38","volume-title":"European Medicines Agency concludes action on COX-2 inhibitors","author":"European Medicines Agency","year":"2005","unstructured":"European Medicines Agency (2005) European Medicines Agency concludes action on COX-2 inhibitors. European Medicines Agency, London"},{"key":"18_CR39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s10620-009-1042-7","volume":"55","author":"LA Feagins","year":"2010","unstructured":"Feagins LA, Cryer BL (2010) Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci 55:226\u2013232","journal-title":"Dig Dis Sci"},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00393-013-1223-9","volume":"72","author":"R Fischer-Betz","year":"2013","unstructured":"Fischer-Betz R, Spathling-Mestekemper S (2013) Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 72:669\u2013682","journal-title":"Z Rheumatol"},{"key":"18_CR41","first-page":"134","volume":"23","author":"PJ Fortun","year":"2007","unstructured":"Fortun PJ, Hawkey CJ (2007) Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 23:134\u2013141","journal-title":"Curr Opin Gastroenterol"},{"key":"18_CR42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","volume":"85","author":"EL Fosbol","year":"2009","unstructured":"Fosbol EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190\u2013197","journal-title":"Clin Pharmacol Ther"},{"key":"18_CR43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2174\/138955706777435661","volume":"6","author":"K Freson","year":"2006","unstructured":"Freson K, Thys C, Wittevrongel C et al (2006) Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem 6:719\u2013726","journal-title":"Mini Rev Med Chem"},{"key":"18_CR44","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/art.20440","volume":"50","author":"JF Fries","year":"2004","unstructured":"Fries JF, Murtagh KN, Bennett M et al (2004) The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 50:2433\u20132440","journal-title":"Arthritis Rheum"},{"key":"18_CR45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","volume":"115","author":"SE Gabriel","year":"1991","unstructured":"Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115:787\u2013796","journal-title":"Ann Intern Med"},{"key":"18_CR46","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2009.02.042","volume":"609","author":"KS Galliard-Grigioni","year":"2009","unstructured":"Galliard-Grigioni KS, Reinhart WH (2009) A randomized, controlled study on the influence of acetaminophen, diclofenac, or naproxen on aspirin-induced inhibition of platelet aggregation. Eur J Pharmacol 609:96\u201399","journal-title":"Eur J Pharmacol"},{"key":"18_CR47","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","volume":"52","author":"LA Garc\u00eda Rodr\u00edguez","year":"2008","unstructured":"Garc\u00eda Rodr\u00edguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with Nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628\u20131636","journal-title":"J Am Coll Cardiol"},{"key":"18_CR48","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","volume":"113","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906\u20132913","journal-title":"Circulation"},{"key":"18_CR49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2006.02867.x","volume":"23","author":"JL Goldstein","year":"2006","unstructured":"Goldstein JL, Miner PB Jr., Schlesinger PK (2006) Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 23:1189\u20131196","journal-title":"Aliment Pharmacol Ther"},{"issue":"280","key":"18_CR50","first-page":"e281","volume":"120","author":"K Gooch","year":"2007","unstructured":"Gooch K, Culleton BF, Manns BJ et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(280):e281\u2013e287","journal-title":"Am J Med"},{"key":"18_CR51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.2007.076760","volume":"68","author":"NJ Goodson","year":"2009","unstructured":"Goodson NJ, Brookhart AM, Symmons DPM et al (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367\u2013372","journal-title":"Ann Rheum Dis"},{"key":"18_CR52","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.clinthera.2011.10.019","volume":"33","author":"M Gore","year":"2011","unstructured":"Gore M, Sadosky A, Leslie D et al (2011) Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 33:1914\u20131931","journal-title":"Clin Ther"},{"key":"18_CR53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/archinte.162.2.169","volume":"162","author":"DY Graham","year":"2002","unstructured":"Graham DY, Agrawal NM, Campbell DR et al (2002) Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169\u2013175","journal-title":"Arch Intern Med"},{"key":"18_CR54","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(13)61128-9","volume":"382","author":"MR Griffin","year":"2013","unstructured":"Griffin MR (2013) High-dose non-steroidal anti-inflammatories: painful choices. Lancet 382:746\u2013748","journal-title":"Lancet"},{"key":"18_CR55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","volume":"116","author":"T Grosser","year":"2006","unstructured":"Grosser T, Fries S, Fitzgerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4\u201315","journal-title":"J Clin Invest"},{"key":"18_CR56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-011209-153129","volume":"61","author":"T Grosser","year":"2010","unstructured":"Grosser T, Yu Y, Fitzgerald GA (2010) Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 61:17\u201333","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"18_CR57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00005344-200605001-00013","volume":"47","author":"CJ Hawkey","year":"2006","unstructured":"Hawkey CJ (2006) NSAIDs, coxibs, and the intestine. J Cardiovasc Pharmacol 47(Suppl 1):72\u201375","journal-title":"J Cardiovasc Pharmacol"},{"key":"18_CR58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","volume":"338","author":"CJ Hawkey","year":"1998","unstructured":"Hawkey CJ, Karrasch JA, Szczepanski L et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338:727\u2013734","journal-title":"N Engl J Med"},{"key":"18_CR59","doi-asserted-by":"crossref","first-page":"f403","DOI":"10.1136\/bmj.f403","volume":"346","author":"K Hawton","year":"2013","unstructured":"Hawton K, Bergen H, Simkin S et al (2013) Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 346:f403","journal-title":"BMJ"},{"key":"18_CR60","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1053\/ajkd.2002.33412","volume":"39","author":"J Henao","year":"2002","unstructured":"Henao J, Hisamuddin I, Nzerue CM et al (2002) Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 39:1313\u20131317","journal-title":"Am J Kidney Dis"},{"key":"18_CR61","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","volume":"160","author":"S Hernandez-Diaz","year":"2000","unstructured":"Hernandez-Diaz S, Rodriguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160:2093\u20132099","journal-title":"Arch Intern Med"},{"key":"18_CR62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2011.200087","volume":"71","author":"B Hinz","year":"2012","unstructured":"Hinz B, Brune K (2012) Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 71:20\u201325","journal-title":"Ann Rheum Dis"},{"key":"18_CR63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"MC Hochberg","year":"2012","unstructured":"Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465\u2013474","journal-title":"Arthritis Care Res"},{"key":"18_CR64","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/bmj.38232.680567.EB","volume":"329","author":"L Hooper","year":"2004","unstructured":"Hooper L, Brown TJ, Elliott R et al (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329:948","journal-title":"BMJ"},{"key":"18_CR65","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2004.12.005","volume":"45","author":"C Huerta","year":"2005","unstructured":"Huerta C, Castellsague J, Varas-Lorenzo C et al (2005) Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45:531\u2013539","journal-title":"Am J Kidney Dis"},{"key":"18_CR66","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-012-0717-6","volume":"48","author":"S Jarupongprapa","year":"2013","unstructured":"Jarupongprapa S, Ussavasodhi P, Katchamart W (2013) Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol 48:830\u2013838","journal-title":"J Gastroenterol"},{"key":"18_CR67","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"KM Jordan","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145\u20131155","journal-title":"Ann Rheum Dis"},{"key":"18_CR68","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J et al (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302\u20131308","journal-title":"BMJ"},{"key":"18_CR69","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1001\/archinte.1996.00440190069008","volume":"156","author":"M Koch","year":"1996","unstructured":"Koch M, Dezi A, Ferrario F et al (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156:2321\u20132332","journal-title":"Arch Intern Med"},{"key":"18_CR70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1755-5922.2011.00283.x","volume":"30","author":"H Krum","year":"2012","unstructured":"Krum H, Swergold G, Gammaitoni A et al (2012) Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 30:342\u2013350","journal-title":"Cardiovasc Ther"},{"key":"18_CR71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00586-010-1541-4","volume":"20","author":"T Kuijpers","year":"2011","unstructured":"Kuijpers T, Van Middelkoop M, Rubinstein SM et al (2011) A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. Eur Spine J 20:40\u201350","journal-title":"Eur Spine J"},{"key":"18_CR72","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.amjmed.2005.04.031","volume":"118","author":"KC Lai","year":"2005","unstructured":"Lai KC, Chu KM, Hui WM et al (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118:1271\u20131278","journal-title":"Am J Med"},{"key":"18_CR73","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","volume":"369","author":"L Laine","year":"2007","unstructured":"Laine L, Curtis SP, Cryer B et al (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369:465\u2013473","journal-title":"Lancet"},{"key":"18_CR74","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2008.149","volume":"104","author":"L Laine","year":"2009","unstructured":"Laine L, Goldkind L, Curtis SP et al (2009) How common is Diclofenac-associated liver injury? analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 104:356\u2013362","journal-title":"Am J Gastroenterol"},{"key":"18_CR75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-9-38","volume":"9","author":"A Lanas","year":"2011","unstructured":"Lanas A, Garcia-Tell G, Armada B et al (2011) Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med 9:38","journal-title":"BMC Med"},{"key":"18_CR76","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","volume":"343","author":"MJ Langman","year":"1994","unstructured":"Langman MJ, Weil J, Wainwright P et al (1994) Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343:1075\u20131078","journal-title":"Lancet"},{"key":"18_CR77","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1572-0241.1998.00588.x","volume":"93","author":"FL Lanza","year":"1998","unstructured":"Lanza FL (1998) A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93:2037\u20132046","journal-title":"Am J Gastroenterol"},{"key":"18_CR78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","volume":"361","author":"TM Macdonald","year":"2003","unstructured":"Macdonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361:573\u2013574","journal-title":"Lancet"},{"key":"18_CR79","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P Mcgettigan","year":"2011","unstructured":"Mcgettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8:e1001098","journal-title":"PLoS Med"},{"key":"18_CR80","doi-asserted-by":"crossref","first-page":"e1001388","DOI":"10.1371\/journal.pmed.1001388","volume":"10","author":"P Mcgettigan","year":"2013","unstructured":"Mcgettigan P, Henry D (2013) Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 10:e1001388","journal-title":"PLoS Med"},{"key":"18_CR81","volume-title":"An evidence-based resource for pain relief","author":"DMRA Mcquay","year":"1998","unstructured":"Mcquay DMRA (1998) An evidence-based resource for pain relief. Oxford University Press, Oxford"},{"key":"18_CR82","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/bmj.314.7093.1531","volume":"314","author":"H Mcquay","year":"1997","unstructured":"Mcquay H, Moore A, Justins D (1997) Treating acute pain in hospital. BMJ 314:1531\u20131535","journal-title":"BMJ"},{"key":"18_CR83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-012-1370-y","volume":"69","author":"IL Meek","year":"2013","unstructured":"Meek IL, Vonkeman HE, Kasemier J et al (2013) Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol 69:365\u2013371","journal-title":"Eur J Clin Pharmacol"},{"key":"18_CR84","unstructured":"MICROMEDEX\u00ae SOLUTIONS (2015) The evidence-based Drug Information System. Truven Health Analytics Inc. \u00a9 2015"},{"key":"18_CR85","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.bjp.0702897","volume":"128","author":"JA Mitchell","year":"1999","unstructured":"Mitchell JA, Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121\u20131132","journal-title":"Br J Pharmacol"},{"key":"18_CR86","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/rheumatology\/ker286","volume":"50","author":"KW Moon","year":"2011","unstructured":"Moon KW, Kim J, Kim JH et al (2011) Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. Rheumatology (Oxford) 50:2278\u20132282","journal-title":"Rheumatology (Oxford)"},{"key":"18_CR87","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT et al (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7:R644\u2013R665","journal-title":"Arthritis Res Ther"},{"key":"18_CR88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.rdc.2008.03.006","volume":"34","author":"RA Moore","year":"2008","unstructured":"Moore RA, Derry S, Mcquay HJ (2008) Topical agents in the treatment of rheumatic pain. Rheum Dis Clin North Am 34:415\u2013432","journal-title":"Rheum Dis Clin North Am"},{"key":"18_CR89","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar2394","volume":"10","author":"RA Moore","year":"2008","unstructured":"Moore RA, Moore OA, Derry S et al (2008) Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther 10:R39","journal-title":"Arthritis Res Ther"},{"key":"18_CR90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.2009.107805","volume":"69","author":"RA Moore","year":"2010","unstructured":"Moore RA, Moore OA, Derry S et al (2010) Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis 69:374\u2013379","journal-title":"Ann Rheum Dis"},{"key":"18_CR91","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1185\/030079907X219553","volume":"23","author":"A Morrison","year":"2007","unstructured":"Morrison A, Ramey DR, Van Adelsberg J et al (2007) Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin 23:2395\u20132404","journal-title":"Curr Med Res Opin"},{"key":"18_CR92","volume-title":"Mutschler Arzneimittelwirkungen: Pharmakologie \u2013 Klinische Pharmakologie \u2013 Toxikologie","author":"E Mutschler","year":"2012","unstructured":"Mutschler E, Geisslinger G, Kroemer HK et al (2012) Mutschler Arzneimittelwirkungen: Pharmakologie \u2013 Klinische Pharmakologie \u2013 Toxikologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart"},{"key":"18_CR93","volume-title":"NICE clinical guideline","author":"National Collaborating Centre for Chronic Conditions, National Institute for Health and Clinical Excellence","year":"2008","unstructured":"National Collaborating Centre for Chronic Conditions, National Institute for Health and Clinical Excellence (2008) Osteoarthritis. The care and management of osteoarthritis in adults. In: Excellence NIfHaC (Hrsg) NICE clinical guideline. NICE, London"},{"key":"18_CR94","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1096\/fj.00-0716fje","volume":"15","author":"E Niederberger","year":"2001","unstructured":"Niederberger E, Tegeder I, Vetter G et al (2001) Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15:1622\u20131624","journal-title":"FASEB J"},{"key":"18_CR95","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT et al (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352:1081\u20131091","journal-title":"N Engl J Med"},{"key":"18_CR96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2012.09.004","volume":"10","author":"CK O\u2019neil","year":"2012","unstructured":"O\u2019neil CK, Hanlon JT, Marcum ZA (2012) Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother 10:331\u2013342","journal-title":"Am J Geriatr Pharmacother"},{"key":"18_CR97","first-page":"804","volume":"29","author":"JJ Ofman","year":"2002","unstructured":"Ofman JJ, Maclean CH, Straus WL et al (2002) A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 29:804\u2013812","journal-title":"J Rheumatol"},{"key":"18_CR98","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nrrheum.2009.103","volume":"5","author":"M Ostensen","year":"2009","unstructured":"Ostensen M, Foerger F (2009) Management of RA medications in pregnant patients. Nat Rev Rheumatol 5:382\u2013390","journal-title":"Nat Rev Rheumatol"},{"key":"18_CR99","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71:1616\u20131622","journal-title":"Ann Rheum Dis"},{"key":"18_CR100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/rheumatology\/kel428","volume":"46","author":"E Rahme","year":"2007","unstructured":"Rahme E, Nedjar H (2007) Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46:435\u2013438","journal-title":"Rheumatology (Oxford)"},{"key":"18_CR101","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","volume":"360","author":"WA Ray","year":"2002","unstructured":"Ray WA, Stein CM, Daugherty JR et al (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360:1071\u20131073","journal-title":"Lancet"},{"key":"18_CR102","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1572-0241.2006.00686.x","volume":"101","author":"J Regula","year":"2006","unstructured":"Regula J, Butruk E, Dekkers CP et al (2006) Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101:1747\u20131755","journal-title":"Am J Gastroenterol"},{"key":"18_CR103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","volume":"69","author":"IA Reilly","year":"1987","unstructured":"Reilly IA, Fitzgerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69:180\u2013186","journal-title":"Blood"},{"key":"18_CR104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/sj.ebd.6400237","volume":"5","author":"D Richards","year":"2004","unstructured":"Richards D (2004) The Oxford Pain Group League table of analgesic efficacy. Evid Based Dent 5:22\u201323","journal-title":"Evid Based Dent"},{"key":"18_CR105","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T et al (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499\u20132512","journal-title":"Arthritis Rheum"},{"key":"18_CR106","doi-asserted-by":"crossref","unstructured":"Rostom A, Dube C, Wells G et al (2002) Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. CD002296","DOI":"10.1002\/14651858.CD002296"},{"key":"18_CR107","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","volume":"5","author":"A Rostom","year":"2007","unstructured":"Rostom A, Muir K, Dube C et al (2007) Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5:818\u2013828 (828 e811\u2013815; quiz 768)","journal-title":"Clin Gastroenterol Hepatol"},{"key":"18_CR108","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1001\/archinte.1993.00410220073008","volume":"153","author":"SH Roth","year":"1993","unstructured":"Roth SH, Tindall EA, Jain AK et al (1993) A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 153:2565\u20132571","journal-title":"Arch Intern Med"},{"key":"18_CR109","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","volume":"101","author":"JM Scheiman","year":"2006","unstructured":"Scheiman JM, Yeomans ND, Talley NJ et al (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101:701\u2013710","journal-title":"Am J Gastroenterol"},{"key":"18_CR110","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1185\/03007990903185706","volume":"25","author":"M Schiff","year":"2009","unstructured":"Schiff M, Hochberg MC, Oldenhof J et al (2009) Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin 25:2471\u20132477","journal-title":"Curr Med Res Opin"},{"key":"18_CR111","first-page":"B4987","volume":"62","author":"M Schmidt","year":"2015","unstructured":"Schmidt M (2015) Cardiovascular risks associated with non-aspirin non-steroidal anti-inflammatory drug use. Dan Med J 62:B4987","journal-title":"Dan Med J"},{"key":"18_CR112","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/aje\/kwj331","volume":"164","author":"V Schneider","year":"2006","unstructured":"Schneider V, Levesque LE, Zhang B et al (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 164:881\u2013889","journal-title":"Am J Epidemiol"},{"key":"18_CR113","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","volume":"364","author":"TJ Schnitzer","year":"2004","unstructured":"Schnitzer TJ, Burmester GR, Mysler E et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665\u2013674","journal-title":"Lancet"},{"key":"18_CR114","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284:1247\u20131255","journal-title":"J Am Med Assoc"},{"key":"18_CR115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"FE Silverstein","year":"1995","unstructured":"Silverstein FE, Graham DY, Senior JR et al (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241\u2013249","journal-title":"Ann Intern Med"},{"key":"18_CR116","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","volume":"56","author":"DL Simmons","year":"2004","unstructured":"Simmons DL, Botting RM, Hla T (2004) Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 56:387\u2013437","journal-title":"Pharmacol Rev"},{"key":"18_CR117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00045391-200007020-00008","volume":"7","author":"G Singh","year":"2000","unstructured":"Singh G (2000) Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 7:115\u2013121","journal-title":"Am J Ther"},{"issue":"Suppl.","key":"18_CR118","first-page":"8","volume":"51","author":"G Singh","year":"1998","unstructured":"Singh G, Rosen Ramey D (1998) NSAID induced gastrointestinal complications: the ARAMIS perspective \u2013 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 51(Suppl.):8\u201316","journal-title":"J Rheumatol"},{"key":"18_CR119","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/ard.2009.122226","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920\u20131925","journal-title":"Ann Rheum Dis"},{"key":"18_CR120","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1001\/archinternmed.2010.391","volume":"170","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Rassen JA, Glynn RJ et al (2010) The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 170:1968\u20131976","journal-title":"Arch Intern Med"},{"key":"18_CR121","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Mcmurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080","journal-title":"N Engl J Med"},{"key":"18_CR122","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon SD, Wittes J, Finn PV et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117:2104\u20132113","journal-title":"Circulation"},{"key":"18_CR123","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2174\/1389557043403783","volume":"4","author":"DO Stichtenoth","year":"2004","unstructured":"Stichtenoth DO (2004) The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev Med Chem 4:617\u2013624","journal-title":"Mini Rev Med Chem"},{"key":"18_CR124","first-page":"44","volume":"45","author":"DO Stichtenoth","year":"1997","unstructured":"Stichtenoth DO, Wagner B, Frolich JC (1997) Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 45:44\u201349","journal-title":"J Investig Med"},{"key":"18_CR125","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1096\/fj.01-0390rev","volume":"15","author":"I Tegeder","year":"2001","unstructured":"Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057\u20132072","journal-title":"FASEB J"},{"key":"18_CR126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/11534590-000000000-00000","volume":"33","author":"MM Tielemans","year":"2010","unstructured":"Tielemans MM, Eikendal T, Jansen JB et al (2010) Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 33:443\u2013453","journal-title":"Drug Saf"},{"key":"18_CR127","doi-asserted-by":"crossref","first-page":"e50836","DOI":"10.1371\/journal.pone.0050836","volume":"7","author":"IM Tleyjeh","year":"2012","unstructured":"Tleyjeh IM, Bin Abdulhak AA, Riaz M et al (2012) Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis. PloS One 7:e50836","journal-title":"PloS One"},{"key":"18_CR128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","volume":"85","author":"MR Tramer","year":"2000","unstructured":"Tramer MR, Moore RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169\u2013182","journal-title":"Pain"},{"key":"18_CR129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1399-6576.1998.tb05083.x","volume":"42","author":"MR Tramer","year":"1998","unstructured":"Tramer MR, Williams JE, Carroll D et al (1998) Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand 42:71\u201379","journal-title":"Acta Anaesthesiol Scand"},{"key":"18_CR130","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342:c7086","journal-title":"BMJ"},{"key":"18_CR131","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/keu408","volume":"54","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Srivali N, Wijarnpreecha K et al (2015) Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford) 54:736\u2013742","journal-title":"Rheumatology (Oxford)"},{"key":"18_CR132","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00228-010-0825-2","volume":"66","author":"KF Vandraas","year":"2010","unstructured":"Vandraas KF, Spigset O, Mahic M et al (2010) Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. Eur J Clin Pharmacol 66:823\u2013829","journal-title":"Eur J Clin Pharmacol"},{"key":"18_CR133","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232\u2013235","journal-title":"Nat New Biol"},{"key":"18_CR134","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/pds.2227","volume":"20","author":"C Varas-Lorenzo","year":"2011","unstructured":"Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2011) Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 20:1225\u20131236","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"18_CR135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3437","volume":"22","author":"C Varas-Lorenzo","year":"2013","unstructured":"Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al (2013) Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 22:559\u2013570","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"18_CR136","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5414\/CPP45281","volume":"45","author":"HE Vonkeman","year":"2007","unstructured":"Vonkeman HE, Fernandes RW, Van De Laar MA (2007) Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 45:281\u2013288","journal-title":"Int J Clin Pharmacol Ther"},{"key":"18_CR137","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semarthrit.2008.08.001","volume":"39","author":"HE Vonkeman","year":"2010","unstructured":"Vonkeman HE, Van De Laar MA (2010) Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 39:294\u2013312","journal-title":"Semin Arthritis Rheum"},{"key":"18_CR138","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0b013e328349de81","volume":"23","author":"X Wang","year":"2011","unstructured":"Wang X, Tian HJ, Yang HK et al (2011) Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol 23:876\u2013880","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"18_CR139","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1096\/fj.03-0645rev","volume":"18","author":"TD Warner","year":"2004","unstructured":"Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 18:790\u2013804","journal-title":"FASEB J"},{"key":"18_CR140","first-page":"2218","volume":"32","author":"CM Wilcox","year":"2005","unstructured":"Wilcox CM, Cryer B, Triadafilopoulos G (2005) Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 32:2218\u20132224","journal-title":"J Rheumatol"},{"key":"18_CR141","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.308.6939.1309a","volume":"308","author":"R Wilkinson","year":"1994","unstructured":"Wilkinson R (1994) Analgesic and NSAID-induced Kidney Disease. BMJ 308:1309","journal-title":"BMJ"},{"key":"18_CR142","unstructured":"Winslow R (2012) Research on Pain Medicines Seeks a Genetic-Trait Link. Wall Str J 5th Aug 2012, Europe edition. http:\/\/www.wsj.com\/articles\/SB10000872396390443545504577567020886039252#articleTabs%3Darticle"},{"key":"18_CR143","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","volume":"338","author":"ND Yeomans","year":"1998","unstructured":"Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719\u2013726","journal-title":"N Engl J Med"},{"key":"18_CR144","first-page":"132ra54","volume":"4","author":"Y Yu","year":"2012","unstructured":"Yu Y, Ricciotti E, Scalia R et al (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4:132ra54 (132ra154)","journal-title":"Sci Transl Med"},{"key":"18_CR145","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","volume":"296","author":"J Zhang","year":"2006","unstructured":"Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619\u20131632","journal-title":"JAMA"},{"key":"18_CR146","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/ard.2004.028886","volume":"64","author":"W Zhang","year":"2005","unstructured":"Zhang W, Doherty M, Arden N et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64:669\u2013681","journal-title":"Ann Rheum Dis"},{"key":"18_CR147","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","volume":"16","author":"W Zhang","year":"2008","unstructured":"Zhang W, Moskowitz RW, Nuki G et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16:137\u2013162","journal-title":"Osteoarthritis Cartilage"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-015-0018-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-015-0018-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-015-0018-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T16:11:52Z","timestamp":1718295112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-015-0018-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s00393-015-0018-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]}}}